Pancreatic NeoplasmsNCT07843147
Studies of Blood Glucose and the Microbiome in Tumors and Cysts of the Pancreas
An observational study of Pancreatic Neoplasms and Pancreatic Cysts, run by Umeå University.
Trial summary
This prospective, single-center observational study investigates whether continuous glucose monitoring (CGM, 14 days) and gut microbiota composition (from a fecal sample) reveal patterns specific to pancreatic cancer, aiming to contribute to earlier detection and better assessment of disease severity. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Pancreatic Neoplasms, Pancreatic Cysts, Hyperglycemia
- How many people
- 100 participants
- Where
- No sites listed yet
- Study dates
- 1 Oct 2026to 1 Oct 2031
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: The study population consists of consecutive adult patients evaluated or treated for pancreatic or periampullary diseases at the Department of Surgery/Cancer Center, Umeå University Hospital, Sweden.
Who may be able to join
- Adults (≥18 years of age).
- Undergoing clinical investigation, follow-up, or treatment for a pancreatic or periampullary condition (malignant or benign/premalignant, including cystic lesions and pancreatitis).
- Willing and able to provide written informed consent for participation in at least one component of the study (continuous glucose monitoring and/or fecal sample collection).
Who cannot join
- -
Trial locations and contacts
No sites are listed yet. Contact the study team or a site near you to ask about taking part.
About this study
This prospective, single-center observational study investigates whether continuous glucose monitoring (CGM, 14 days) and gut microbiota composition (from a fecal sample) reveal patterns specific to pancreatic cancer, aiming to contribute to earlier detection and better assessment of disease severity. Adult patients under investigation, follow-up, or treatment for benign or malignant pancreatic/periampullary conditions are invited to participate in either or both parts of the study.
Read the detailed description
See Appendix 1 (Research Plan) for a full description of the background, aims, and methods.
- Conditions
- Pancreatic Neoplasms, Pancreatic Cysts, Hyperglycemia, Prediabetes
- Keywords
- continuous glucose monitoring, gut microbiota, pancreatic cancer, biomarker, fecal microbiome
- Medical subject headings
- Pancreatic Neoplasms, Pancreatic Cyst, Hyperglycemia, Prediabetic State
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
| Study group | Role | What they receive |
|---|---|---|
| Patients with pancreatic cancer | Not described | |
| Patients with cysts or other benign pancreatic disease | Not described |
What is being measured
The primary outcome is the main question the study is designed to answer.
Difference in CGM-derived glycemic variability metrics
Measured: 14 days CGM recording period
Difference in gut microbiota composition
Measured: Single fecal sample
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted25 Sep 2026
- Study start1 Oct 2026 (estimated)
- Primary completion1 Oct 2029 (estimated)
- Study completion1 Oct 2031 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Pancreatic NeoplasmsStudies of the same condition, open and under way.
- More trials run by Umeå UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 100 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Umeå University
- Sponsor type
- University, hospital or other
- Collaborators
- Region Västerbotten
- Responsible party
- Sponsor
- Investigators
- Oskar Franklin, M.D, PhD, Principal investigator, Umeå University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07843147
- Sponsor's protocol ID
- 2026-03261
- Status last verified
- Sep 2026
- First submitted
- 21 Sep 2026
- Last updated
- 25 Sep 2026
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: De-identified individual participant data may be shared with qualified researchers upon reasonable request where permitted by applicable legislation, ethical approvals, and participant consent. Data access requests will be reviewed by the study investigators and the responsible institution. Data sharing may require additional ethical approval and a data sharing agreement. Requests that cannot be accommodated under Swedish and EU data protection regulations will not be approved.
Study at a glance
From the registry record, last updated by the sponsor on 25 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Studies of Blood Glucose and the Microbiome in Tumors and Cysts of the Pancreas
- ClinicalTrials.gov ID
- NCT07843147
- Acronym / sponsor ID
- 2026-03261
- Conditions
- Pancreatic Neoplasms, Pancreatic Cysts, Hyperglycemia, Prediabetes
- Keywords
- continuous glucose monitoring, gut microbiota, pancreatic cancer, biomarker, fecal microbiome
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 100 participants (estimated)
- Lead sponsor
- Umeå UniversityUniversity, hospital or other
- Collaborators
- Region Västerbotten
- Study start
- 1 Oct 2026 (estimated)
- Primary completion
- 1 Oct 2029 (estimated)
- Study completion
- 1 Oct 2031 (estimated)
- First posted
- 25 Sep 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
This prospective, single-center observational study investigates whether continuous glucose monitoring (CGM, 14 days) and gut microbiota composition (from a fecal sample) reveal patterns specific to pancreatic cancer, aiming to contribute to earlier detection and better assessment of disease severity. Adult patients under investigation, follow-up, or treatment for benign or malignant pancreatic/periampullary conditions are invited to participate in either or both parts of the study.
Detailed description
See Appendix 1 (Research Plan) for a full description of the background, aims, and methods.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
- Number of arms
- 2
| Arm | Type | Receives |
|---|---|---|
| Patients with pancreatic cancer | – | – |
| Patients with cysts or other benign pancreatic disease | – | – |
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- The study population consists of consecutive adult patients evaluated or treated for pancreatic or periampullary diseases at the Department of Surgery/Cancer Center, Umeå University Hospital, Sweden.
Key inclusion criteria (3 listed)
- Adults (≥18 years of age).
- Undergoing clinical investigation, follow-up, or treatment for a pancreatic or periampullary condition (malignant or benign/premalignant, including cystic lesions and pancreatitis).
- Willing and able to provide written informed consent for participation in at least one component of the study (continuous glucose monitoring and/or fecal sample collection).
Key exclusion criteria (1 listed)
- -
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Primary outcome
Difference in CGM-derived glycemic variability metrics
Time frame: 14 days CGM recording period
Difference in gut microbiota composition
Time frame: Single fecal sample
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 25 Sep 2026.
- Individual participant dataSharing planned: Yes. De-identified individual participant data may be shared with qualified researchers upon reasonable request where permitted by applicable legislation, ethical approvals, and participant consent. Data access requests will be reviewed by the study investigators and the responsible institution. Data sharing may require additional ethical approval and a data sharing agreement. Requests that cannot be accommodated under Swedish and EU data protection regulations will not be approved.
Related trials for Pancreatic Neoplasms
Enrolling by invitationPhase 2
A Single-Arm Study of Nimotuzumab Combined With NALIRIFOX as First-Line Treatment for Pancreatic Cancer
Pancreatic Cancer Metastatic
RecruitingPhase 2/3
Multicenter Validation Trial of [18F]AlF-FAPI-74 for PET Imaging of Cancer-associated Fibroblasts Through Fibroblast Activation Protein Inhibitors (FAPI) in Different Tumor Types
Oesophageal Cancer, Gastric Cancer
RecruitingPhase 1
Modified FOLFIRINOX and Pentamidine in Advanced and Metastatic Pancreatic Cancer
Pancreatic Ductal Adenocarcinoma (PDAC)
RecruitingPhase 3
Atebimetinib + GnP as a First Line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma
Pancreatic Cancer, Pancreatic Cancer Metastatic
RecruitingPhase 3
Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula
Pancreatic Carcinoma, Pancreatic Neoplasm
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Oskar Franklin, M.D, PhD principal investigator
Umeå University
Questions about this trial
What is this clinical trial studying?
An observational study of Pancreatic Neoplasms and Pancreatic Cysts, run by Umeå University.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 3 inclusion and 1 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 25 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Oskar Franklin, M.D, PhD (+46 90 7865000, oskar.franklin@umu.se), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Difference in CGM-derived glycemic variability metrics (time frame: 14 days CGM recording period). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 25 Sep 2026.